MyFinsight
Home
Blog
About
logo_teva-svg
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
logo_teva-svg
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$306M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
Acquired ipr&d related to emalex...
Beneficial interest collected in...
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Purchase of emalex biosciences o...
Net income (loss)
Net change in operating assets a...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-575
369
481
434
Depreciation and amortization
241
239
260
248
Impairment of goodwill
-
-
0
0
Impairment of long-lived assets and assets held for sale
112
10
773
78
Acquired ipr&d related to emalex biosciences, see note 2
724
-
-
-
Net change in operating assets and liabilities
163
617
-229
560
Deferred income taxes net and uncertain tax positions
25
-22
-595
107
Stock-based compensation
40
43
51
34
Other items
18
-54
-41
28
Net loss (gain) from sale of business and long-lived assets
12
8
0
0
Net cash provided by (used in) operating activities
411
-40
1,158
369
Beneficial interest collected in exchange for securitized trade receivables
311
354
282
274
Purchases of property, plant and equipment and intangible assets
105
168
142
136
Proceeds from sale of business and long-lived assets, net
4
42
0
8
Proceeds from sale of investments
-
-
42
0
Acquisitions of businesses, net of cash acquired
-
-
0
0
Purchase of emalex biosciences outstanding shares, see note 2
696
-
-
-
Purchases of investments and other assets
1
0
17
13
Other investing activities
4
-1
0
-2
Net cash provided by (used in) investing activities
-492
229
165
135
Repayment of senior notes and loans and other long term liabilities
-
-
0
444
Proceeds from senior notes, net of issuance costs
-
-
-7
-
Proceeds from short term debt
-
-
0
-
Repayment of senior notes and loans and other long-term liabilities
23
0
-
-
Proceeds from senior notes, net of issuance costs
-
-
-
2,298
Repayment of short term debt
-
-
0
-
Repayment of convertible debentures
-23
23
-
-
Purchase of shares from redeemable and non-redeemable non-controlling interests
0
0
0
0
Dividends paid to redeemable and non-redeemable non-controlling interests
0
0
0
0
Other financing activities
-1
36
40
-2
Net cash provided by (used in) financing activities
-1
13
40
-453
Effect of exchange rate changes on cash and cash equivalents
-5
-17
-10
-9
Net change in cash and cash equivalents
-86
185
1,353
42
Balance of cash and cash equivalents at beginning of period
3,741
3,556
1,697
1,697
Balance of cash and cash equivalents at end of period
3,655
3,741
3,556
2,203
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Acquired ipr&d related to
emalex biosciences,...
$724M
Depreciation and
amortization
$241M
(-3.60%↓ Y/Y)
Impairment of long-lived
assets and assets held...
$112M
(12.00%↑ Y/Y)
Stock-based compensation
$40M
(5.26%↑ Y/Y)
Deferred income taxes net
and uncertain tax...
$25M
(111.85%↑ Y/Y)
Other items
$18M
(-82.35%↓ Y/Y)
Net cash provided by
(used in) operating...
$411M
(81.06%↑ Y/Y)
Canceled cashflow
$750M
Net change in cash
and cash...
-$86M
(-118.53%↓ Y/Y)
Canceled cashflow
$411M
Beneficial interest
collected in exchange for...
$311M
(-7.44%↓ Y/Y)
Proceeds from sale of
business and long-lived...
$4M
(-55.56%↓ Y/Y)
Net income (loss)
-$575M
(-303.18%↓ Y/Y)
Net change in
operating assets and...
$163M
(-51.34%↓ Y/Y)
Net loss (gain) from
sale of business and...
$12M
Net cash provided by
(used in) investing...
-$492M
(-308.47%↓ Y/Y)
Canceled cashflow
$315M
Effect of exchange rate
changes on cash and cash...
-$5M
(0.00%↑ Y/Y)
Purchase of emalex
biosciences outstanding...
$696M
Purchases of property,
plant and equipment...
$105M
(9.38%↑ Y/Y)
Other investing
activities
$4M
(233.33%↑ Y/Y)
Purchases of investments
and other assets
$1M
(-93.75%↓ Y/Y)
Buy us a coffee
🚨
Price Alert:
The stock price jumped by 10.72% after the earning call.
Show more